Compare ATHM & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATHM | GHRS |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | China | Ireland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2013 | 2021 |
| Metric | ATHM | GHRS |
|---|---|---|
| Price | $20.77 | $21.07 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 10 |
| Target Price | $21.40 | ★ $42.89 |
| AVG Volume (30 Days) | ★ 365.4K | 268.4K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 8.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.59 | N/A |
| P/E Ratio | $12.13 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.57 | $12.04 |
| 52 Week High | $28.08 | $31.44 |
| Indicator | ATHM | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 41.82 | 29.00 |
| Support Level | $20.62 | $19.75 |
| Resistance Level | $22.24 | $22.88 |
| Average True Range (ATR) | 0.51 | 1.36 |
| MACD | -0.04 | -0.39 |
| Stochastic Oscillator | 32.86 | 14.39 |
Founded in 2008 as a media content platform, Autohome is the leading online automobile platform in China, ranking first among automotive service platforms in terms of mobile daily active users, according to QuestMobile. Through its two websites, autohome.com.cn and che168.com, Autohome delivers comprehensive, independent, and interactive content and tools to automobile consumers as well as a full suite of services to automakers and dealers. According to iResearch, the company was the largest online automotive advertising and lead-generation service provider in China's online auto platform media advertising market, in terms of media services and lead-generation revenue.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.